Skip to content

Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury

Development of a Spinal Cord Injury-specific Exercise-based Capacity

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02602639
Acronym
FES
Enrollment
6
Registered
2015-11-11
Start date
2015-10-31
Completion date
2022-09-30
Last updated
2020-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraplegia, Spinal Cord Injury, Tetraplegia

Brief summary

Currently, those with spinal cord injury (SCI) demonstrate increased prevalence of obesity (75%) cardiovascular disease (30 - 50%), type II diabetes (21%) and osteoporosis in the legs (100%) when compared to the general population. It is important to identify the modes and intensities of exercise most likely to generate a reduction in these inactivity-related diseases in this population. Therefore, the main purpose of this pilot research project is to implement and test a form of a spinal cord injury-specific exercise, known as FES rowing (FES: functional electrical stimulation).

Interventions

DEVICEFunctional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)

Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.

Sponsors

University of Manitoba
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Have a spinal cord injury, C5-T12 (level), AIS A-D (severity) * Be aged 18-75 for duration of study * Medically stable and healthy enough to complete exercise requirements * Willing and able to complete the at-home training requirements as prescribed * Willing and able to complete the exercise sessions as prescribed * Willing and able to complete the VO2 testing throughout the study * Willing and able to complete the DEXA (Dual-energy X-ray absorptiometry) scans during the study * Able to understand and follow written or verbal instructions from study staff

Exclusion criteria

* Current pressure ulcer(s) at sites of electrical stimulation * Previous spontaneous or low-impact leg fracture * Previous diagnosis of cardiovascular disease (ie enlarged heart, heart murmur) * Unsatisfactory results of EKG (electrocardiogram) screening test * Known thyroid dysfunction * Kidney disease * Cancer * Blood pressure \> 140/90 mmHg * Currently taking blood pressure medication * History of epilepsy * Current hand, arm or shoulder injury * Current deep vein thrombosis * Implanted electronic cardiac device (pace maker, defibrillator, etc) * Ventilator-dependent * Unable to follow written and verbal instructions

Design outcomes

Primary

MeasureTime frameDescription
Peak VO2 (volume oxygen) output during exercise24 weeks compared to baselinePeak VO2 testing will be performed before beginning rower training and again at the end of the 24 weeks of training. Testing will be performed with an arm ergometer, rowing without electrical stimulation, and rowing with electrical stimulation. This will assess energy use, time to fatigue, and perceived exertion.

Secondary

MeasureTime frameDescription
Body composition24 weeks compared to baselineParticipants will have their body composition (specifically leg percent fat and muscle, and bone mineral density) measured before beginning training and at the end of the 24 weeks of training.
Leg EMG (electromyogram) while rowingThroughout study (up to 36 weeks)Participants will perform the rowing exercise while having EMG of multiple leg muscles.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026